Longeveron (LGVN) Interest Expenses (2020 - 2026)
Longeveron's (LGVN) quarterly Interest Expenses came in at $770000.0 in Q1 2026, down 41.44% year-on-year from $1.3 million in Q1 2025, and down 9.73% quarter-over-quarter from $853000.0 in Q4 2025.
Longeveron (LGVN) Interest Expenses (2020 - 2026) Analysis & Trends
Longeveron's Interest Expenses history runs 7 years deep, the most recent figure standing at $770000.0 for Q1 2026.
- On a quarterly basis, Interest Expenses fell 41.44% year-over-year to $770000.0 in Q1 2026; TTM through Mar 2026 was $770000.0, a 41.44% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 94.15% from the prior year.
- Interest Expenses slipped to $770000.0 in Q1 2026 per LGVN's latest filing, from $853000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $38.0 million in Q1 2023 and bottomed at -$12000.0 in Q4 2022.
- The 5-year median for Interest Expenses is $702000.0 (2022), against an average of $2.8 million.
- Across the five-year window, Interest Expenses jumped 5313.11% in 2023 and tumbled 99.41% in 2024, its largest moves.
- Year by year, Interest Expenses stood at -$12000.0 in 2022, then jumped by 358.33% to $31000.0 in 2023, then soared by 3012.9% to $965000.0 in 2024, then slipped by 11.61% to $853000.0 in 2025, then slipped by 9.73% to $770000.0 in 2026.
- Per Business Quant, the three latest LGVN Interest Expenses figures stand at $770000.0 (Q1 2026), $853000.0 (Q4 2025), and $1.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 | 770,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 770,000.00 |
| Mar 31, 2026 | 770,000.00 |
| Dec 31, 2025 | 853,000.00 |
| Dec 31, 2025 | 853,000.00 |
| Sep 30, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 965,000.00 |
| Dec 31, 2024 | 965,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |